Navigation Links
ImaRx Postpones Release of First Quarter 2008 Financial Results
Date:5/13/2008

Live Webcast and Conference Call Scheduled for Thursday, May 15th at 5 PM

ET

TUCSON, Ariz., May 13 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) today announced that the Company has postponed its live webcast and conference call to Thursday, May 15, 2008, at 5:00 p.m. ET to discuss first quarter 2008 financial results; this call was originally scheduled for Tuesday, May 13, 2008, at 5:00 p.m. ET.

The live webcast can be accessed through ImaRx's corporate website at http://www.imarx.com and will be archived on the website for 14 days following the event.

Interested parties may access the conference call by dialing (877) 407-4018 in the U.S. and Canada or (201) 689-8471 internationally. A telephonic replay will be available through May 22, 2008 by dialing (877) 660-6853 in the U.S. and Canada or (201) 612-7415 internationally (Account Number 3055 and Conference ID 284385).

About ImaRx Therapeutics

ImaRx Therapeutics is a biopharmaceutical company developing and commercializing therapies for vascular disorders. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology. The Company's commercialization efforts are currently focused on its product, urokinase, for the treatment of acute massive pulmonary embolism.

Contacts:

The Ruth Group (Investors/Media)

Sara Ephraim/Jason Rando

646-536-7002 or 7025

sephraim@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. ImaRx Schedules Release of First Quarter 2008 Financial Results
2. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
3. ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
4. ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQs Minimum Bid Price Requirement
5. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
6. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
7. ImaRx to Report Corporate Updates and 4Q07 Financial Results
8. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
9. Chem Rx Corporation Postpones Conference Call to Review Full Year 2007 Financial Results
10. BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
11. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., ... Schmidt , Ph.D., as chief executive officer, as ... directors. Dr. Schmidt brings to ArmaGen more than 17 ... research and development of biotherapeutics and pharmaceuticals. ... with the diverse experience and skillset necessary to ...
(Date:1/19/2017)... Minnesota (PRWEB) , ... January 19, 2017 , ... ... research organization with services spanning the full spectrum of drug and device development, ... research services to pharma/device companies and clinicians, today announced Verified Clinical Trials ...
(Date:1/18/2017)... ... January 18, 2017 , ... Opal Kelly, a leading producer ... Express, announced the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed USB 3.0 ... form factor suitable for prototyping, testing, and production-ready integration. The ZEM5310 USB interface ...
(Date:1/18/2017)... ... January 18, 2017 , ... Executive search ... in its continued commitment to the advancement of the clinical trials segment. Hosted ... related to clinical trial planning and management. , As executive talent specialists ...
Breaking Biology Technology:
(Date:1/18/2017)... MINNETONKA, Minn. , Jan. 18, 2017 /PRNewswire/ ... eClinical technology company that supports the entire spectrum ... 2016 has been another record-breaking year for the ... and market interest in MedNet,s eClinical products and ... to the tremendous marketplace success of ...
(Date:1/12/2017)... 2017  Trovagene, Inc. (NASDAQ: TROV ), ... announced that it has signed agreements with seven strategic ... Middle East for commercialization of ... first wave of international distribution agreements for Trovagene,s CLIA ... The initial partners will introduce Trovagene,s liquid ...
(Date:1/12/2017)... Oregon and PUNE, India , January 12, 2017 /PRNewswire/ ... Market: Opportunities and Forecasts, 2015 - 2022," projects that the global biometric technology market ... of 19.4% from 2016 to 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):